Jean Bizzari
Director/Board Member chez ADC THERAPEUTICS SA
Fortune : 3 M $ au 31/03/2024
Profil
Dr. Jean P.
Bizzari, MD, is an Independent Director at Aprea Therapeutics, Inc., a Chairman at NETRIS Pharma SAS and a President & Director at Synergie Lyon Cancer.
He is on the Board of Directors at Aprea Therapeutics, Inc., ADC Therapeutics SA, European Organisation for Research & Treatment of Cancer, Oxford BioTherapeutics Ltd., International Drug Development Institute SA and Synergie Lyon Cancer.
Dr. Bizzari was previously employed as an Independent Director by Nordic Nanovector ASA, an Independent Director by Valerio Therapeutics SA, an Independent Director by Pieris Pharmaceuticals, Inc., an Independent Director by Celator Pharmaceuticals, Inc., an Independent Director by Halozyme Therapeutics, Inc., an Executive Vice President & Global Head-Oncology by Celgene Corp., an Independent Director by Transgene SA, a Vice President-Clinical Oncology Development by Sanofi-Aventis Pharmaceuticals, a Vice President-Clinical Development Oncology by Sanofi-Synthelabo, Inc., a Vice President-Clinical Development Oncology by Rhone Poulenc Rorer, a Vice President-Clinical Oncology by Rhône-Poulenc, Inc., a Head-Oncology by Institut de Recherches Internationales Servier, and a Vice President-Clinical Development by Aventis, Inc. He also served on the board at Compugen Ltd., Theravectys SAS and iTeos Therapeutics SA. He received his graduate degree from the University of Nice Sophia Antipolis and a doctorate degree from the University of Nice Sophia Antipolis.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 26/02/2024 | 58 750 ( 0,05% ) | 2 M $ | 31/03/2024 | |
ADC THERAPEUTICS LTD
0,05% | 01/02/2024 | 39 387 ( 0,05% ) | 176 848 $ | 31/03/2024 |
Postes actifs de Jean Bizzari
| Sociétés | Poste | Début |
|---|---|---|
| ADC THERAPEUTICS SA | Director/Board Member | 01/07/2022 |
| APREA THERAPEUTICS, INC. | Director/Board Member | 23/08/2023 |
NETRIS Pharma SAS
 NETRIS Pharma SAS BiotechnologyHealth Technology NETRIS Pharma SAS develops targeted therapies for the treatment of cancer. The company is based in Lyon, France. The French company was founded in 2008 by Patrick Mehlen, Agnès Bernet. Patrick Mehlen has been the CEO since 2008. | Chairman | - |
International Drug Development Institute SA
 International Drug Development Institute SA Miscellaneous Commercial ServicesCommercial Services International Drug Development Institute SA engages in the provision of biostatistics and electronical-clinical solutions for phase I-IV clinical trials. It offers oncology clinical research, consultancy, clinical data management, data standards implementation and randomization services. The company was founded by Marc Buyse in 1991 and is headquartered in Louvain-la-Neuve, Belgium. | Director/Board Member | - |
Synergie Lyon Cancer
 Synergie Lyon Cancer Miscellaneous Commercial ServicesCommercial Services Synergie Lyon Cancer provides health care services. It focuses on research efforts on cancer escape, apoptosis and senescence and Immune surveillance. The company was founded in 2007 and is headquartered in Lyon, France. | President | - |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Director/Board Member | 16/12/2016 |
| European Organisation for Research & Treatment of Cancer | Director/Board Member | - |
Anciens postes connus de Jean Bizzari
| Sociétés | Poste | Fin |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Director/Board Member | 25/04/2024 |
| COMPUGEN LTD. | Director/Board Member | 01/03/2022 |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Jean Bizzari
| University of Nice Sophia Antipolis | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 7 |
|---|---|
| COMPUGEN LTD. | Health Technology |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| TRANSGENE | Health Technology |
| VALERIO THERAPEUTICS | Health Technology |
| ADC THERAPEUTICS SA | Health Technology |
| PIERIS PHARMACEUTICALS, INC. | Health Technology |
| APREA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 16 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
| Aventis, Inc. | |
Celator Pharmaceuticals, Inc.
 Celator Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Celator Pharmaceuticals, Inc. engages in the research and development of biopharmaceutical products. The company was founded by Lawrence David Mayer, and Marcel B. Bally in 1999 and is headquartered in Ewing, NJ. | Health Technology |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Rhone Poulenc Rorer
 Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products. | Process Industries |
| Sanofi-Synthelabo, Inc. | Health Technology |
| Rhône-Poulenc, Inc. | Process Industries |
| Sanofi-Aventis Pharmaceuticals | |
Synergie Lyon Cancer
Synergie Lyon Cancer Miscellaneous Commercial ServicesCommercial Services Synergie Lyon Cancer provides health care services. It focuses on research efforts on cancer escape, apoptosis and senescence and Immune surveillance. The company was founded in 2007 and is headquartered in Lyon, France. | Commercial Services |
| European Organisation for Research & Treatment of Cancer | |
International Drug Development Institute SA
International Drug Development Institute SA Miscellaneous Commercial ServicesCommercial Services International Drug Development Institute SA engages in the provision of biostatistics and electronical-clinical solutions for phase I-IV clinical trials. It offers oncology clinical research, consultancy, clinical data management, data standards implementation and randomization services. The company was founded by Marc Buyse in 1991 and is headquartered in Louvain-la-Neuve, Belgium. | Commercial Services |
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
Institut de Recherches Internationales Servier
 Institut de Recherches Internationales Servier Miscellaneous Commercial ServicesCommercial Services Part of Servier SAS, Institut de Recherches Internationales Servier is a French company that provides scientific research and development services. The private company is based in Suresnes, France. | Commercial Services |
NETRIS Pharma SAS
NETRIS Pharma SAS BiotechnologyHealth Technology NETRIS Pharma SAS develops targeted therapies for the treatment of cancer. The company is based in Lyon, France. The French company was founded in 2008 by Patrick Mehlen, Agnès Bernet. Patrick Mehlen has been the CEO since 2008. | Health Technology |
Theravectys SAS
 Theravectys SAS BiotechnologyHealth Technology Theravectys SAS provides biotechnology research services. It is working on the development of a therapeutic vaccine against HIV. The company was founded on May 17, 2005 and is headquartered in Paris, France. | Health Technology |
